India, Aug. 11 -- Sentynl Therapeutics, Inc., a unit of Zydus Lifesciences Limited, on Tuesday said it has entered into an option and license agreement with Mereo BioPharma Group plc (MREO) for U.S. commercial and global manufacturing rights to alvelestat for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD).
Alvelestat is being prepared for a Phase 3 study and, if approved, could become the first oral treatment for AATD-LD, a rare and progressive genetic lung disease estimated to affect 50,000 to 80,000 people in the U.S.
Under the agreement, Sentynl has the exclusive right to acquire a license to commercialize alvelestat for AATD-LD in the U.S., while Mereo will retain commercial rights in other markets. Sentynl will also...